Behavioral Pharmacology Laboratory
Mary Worrel Hulin, MD/PhD student
Peter F. Weed, PhD student
Blake Lewis, BS, research associate
For the past fifteen years, my research projects have focused primarily on the behavioral pharmacology of all classes of drugs of abuse, including alcohol, in a variety of animal species. Recently, in collaboration with Louisiana State University’s Alcohol Research Center, my laboratory began studies aimed at evaluating the neuropsychological deficits produced by alcohol and marijuana in SIV-infected rhesus monkeys. By participating in these studies, I also became interested in how drug abuse during adolescence can produce long-term deficits in brain function. Drug abuse during adolescence, a significant period of maturation, may enhance an individual’s vulnerability to the central nervous system (CNS) dysfunction and could produce persistent changes in the brain that could set the stage for a lifetime of mental health issues such as drug taking or abuse. To enhance our understanding of these complex issues, my laboratory is now collaborating with several of my colleagues interested in molecular biology in order to enhance the breadth of the research conducted by my laboratory. The primary reason for this is that I believe the future of pharmacology lies in the study of the interface between specific molecular and behavioral mechanisms.
National Institute on Drug Abuse.
R01 DA019625: Effects of chronic THC in adolescence, Principle Investigator.
R01 DA020419: Cannabinoid effects on HIV/AIDS, Co-Investigator.
R01 DA030053: Cannabinoid Epigenomic and miRNA mechanisms impact HIV/SIV disease progression, Co-Investigator.
Department of Defense.
CDMRP, DMRDP: Endocannabinoids as a target for the treatment of traumatic brain injury, Co-Investigator.
National Center for Research Resources
2P20RR018766-08: Mentoring in Cardiovascular Biology, Mentor.
National Institute on Alcohol Abuse and Alcoholism
T32 AA07577-06: Biomedical Alcohol Research Training Program, Core Faculty Member.
F30 AA019848-01: A preclinical evaluation of DHEA as a treatment for alcoholism, Sponsor.